Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
about
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerRapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Nephrotoxicity of recent anti-cancer agents.Therapeutic advances in women's cancersClinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a reviewAdverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib.Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.
P2860
Q24595773-4539A568-6E90-4845-AB38-0BC9066CCD2CQ33684042-CDB9398C-DDBE-41FA-8944-EAE70329E38EQ33828690-D7C6A785-4D32-441D-8CB7-54549BA80B42Q34803030-445B9B3E-27F5-4CB2-A806-00CC8BF9F9A9Q35310741-4136B9D2-8DA5-4584-AEBE-04BC5D68AE08Q35418973-FD1B1A7C-15AF-42C9-B959-44EBF5EA0C97Q35599819-4718A3E9-CD9B-46CA-B8FA-1793FB89BB3BQ36061770-04027D95-4A00-4BF9-852E-A4E6E669511FQ36075546-9CB89819-DBA0-4FFF-B120-EAD2E4CC6DEAQ37345045-CFFE4A8B-5AEC-463C-8081-24BE0C63478FQ38225636-474E0767-A1E0-4C6A-833E-D30EBC26E9B2Q38261105-5F6E7EFC-CDB0-494F-B3B3-952E14972EEFQ41524516-74A0E16B-52E1-485D-A7BC-63E4664346ADQ42323403-B03D2A02-39A2-4526-8F97-4924877ED235Q50164526-FC216414-8DAE-441D-8D6D-B6A79A074FCF
P2860
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@ast
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@en
type
label
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@ast
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@en
prefLabel
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@ast
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@en
P2860
P1433
P1476
Cardiovascular toxicities: clu ...... signaling pathway inhibitors.
@en
P2093
Kelly L Snider
Michael L Maitland
P2860
P2888
P356
10.1007/S11523-009-0106-0
P577
2009-04-17T00:00:00Z